The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Evolution of Personalized Dosimetry for Radioembolization of Hepatocellular Carcinoma
J Vasc Interv Radiol. 2023 Mar 26;S1051-0443(23)00223-3.doi: 10.1016/j.jvir.2023.03.011. Online ahead of print.
1From the Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, Illinois.
2From the Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, Illinois. Electronic address: r-lewandowski@northwestern.edu.
Abstract
Yttrium-90 transarterial radioembolization (TARE) has progressed from a salvage or palliative lobar or sequential bilobar regional liver therapy for patients with advanced disease to a versatile, potentially curative, and often highly selective local treatment for patients across Barcelona Clinic Liver Cancer stages. With this shift, radiation dosimetry has evolved to become more tailored to patients and target lesion(s), with treatment dose and distributions adapted for specific clinical goals (ie, palliation, bridging or downstaging to liver transplantation, converting to surgical resection candidacy, or ablative/curative intent). Data have confirmed that "personalizing" dosimetry yields real-world improvements in tumor response and overall survival while maintaining a favorable adverse event profile. In this review, imaging techniques used before, during, and after TARE have been reviewed. Historical algorithms and contemporary image-based dosimetry methods have been reviewed and compared. Finally, recent and upcoming developments in TARE methodologies and tools have been discussed.